COMMUNIQUÉS West-GlobeNewswire

LeMaitre Q3 2024 Financial Results
31/10/2024
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided [...]
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
31/10/2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2024 financial results will be released after market close on [...]
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
31/10/2024
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that [...]
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
31/10/2024
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced [...]
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
31/10/2024
First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conference Our partner Jazz Pharmaceuticals [...]
Codexis Reports Third Quarter 2024 Financial Results
31/10/2024
Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue [...]
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
31/10/2024
Winner to be Presented at BIO-Europe 2024 in Stockholm, Sweden ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics [...]
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
31/10/2024
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue [...]
NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System
31/10/2024
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets Agreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE [...]
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
31/10/2024
Iovance also to Participate in Upcoming November Conferences SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing [...]
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
31/10/2024
Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3 rd line [...]
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
31/10/2024
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31/10/2024
CHICAGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- On October 28, 2024, the Foundation for Sarcoidosis Research (FSR) hosted a groundbreaking Externally Led Patient-Focused Drug Development (EL-PFDD) meeting on sarcoidosis with [...]
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
31/10/2024
WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
HWH International Announces its Upcoming Launch of the Hapi Wealth Program
31/10/2024
Bethesda, MD, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH” or the “Company”) (Nasdaq: HWH) is pleased to announce that the Company has scheduled the launch of Hapi Wealth, a program dedicated to [...]
Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak
31/10/2024
Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the open-label clinical trial. WASHINGTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- In continued [...]
KFSHRC Leads Ethical Integration of AI in Healthcare
31/10/2024
RIYADH, Saudi Arabia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Responsible integration has become imperative as Artificial Intelligence (AI) continue to reshape the medical landscape. King Faisal Specialist Hospital & [...]
GUERBET : Financial agenda for 2025
31/10/2024
Financial agenda for 2025 Villepinte, 31 October 2024 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications [...]
GUERBET : Calendrier financier de l'exercice 2025
31/10/2024
Calendrier financier de l’exercice 2025 Villepinte, le 31 octobre 2024 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier [...]

Pages